A Narrative Review of the Evolving Landscape of the Management of Metastatic Gastric Cancer: the Role of Targeted Therapies

Overview

Journal J Gastrointest Oncol

Date 2024 Jan 10

PMID 38196524

Authors

Glenda M Delgado-Ramos

Jack Fitzsimons

Asha Dhanarajan

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Gastric cancer is the fifth most common cancer worldwide and the fourth leading cause of cancer-related death. Unfortunately, patients often present with advanced disease at diagnosis, which is directly related to its high mortality. Numerous trials, as early as the 1980's, have shown that cytotoxic chemotherapy improves survival. This review will focus on targeted therapies and immunotherapies which have emerged as treatment options for metastatic gastric cancer, often used in conjunction with cytotoxic chemotherapy. Here we will review the relevant clinical trials of targeted therapies and immunotherapies in the treatment of metastatic gastric cancer.

Methods: We performed an extensive review of articles in the PubMed database pertaining to targeted therapies and immunotherapies in the treatment of metastatic gastric cancer. Additionally, updated guidelines from the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) were reviewed.

Key Content And Findings: Cytotoxic chemotherapy remains the backbone of treatment of metastatic gastric cancer, but the development of targeted therapies and immunotherapy have revolutionized its treatment with improved survival and outcomes. Therapies have been developed which target human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor-2 (VEGFR-2), and tyrosine kinase pathways. Novel targeted therapies are currently being investigated with promising results thus far. Immunotherapy, specifically immune checkpoint inhibitors (ICIs), has proven to be a significant advancement in the treatment of gastric cancer.

Conclusions: Targeted therapies and immunotherapies have improved survival and outcomes in metastatic gastric cancer, however more research is needed to make even greater strides.

Citing Articles

Causal relationship between circulating immune cells and gastric cancer: a bidirectional Mendelian randomization analysis using UK Biobank and FinnGen datasets.

Yang W, Ou Y, Luo H, You L, Du H Transl Cancer Res. 2024; 13(9):4702-4713.

PMID: 39430856 PMC: 11483344. DOI: 10.21037/tcr-24-480.

References

Klapper L, Glathe S, Vaisman N, Hynes N, ANDREWS G, Sela M . The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A. 1999; 96(9):4995-5000. PMC: 21805. DOI: 10.1073/pnas.96.9.4995. View

Shitara K, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K . Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10):1571-1580. PMC: 7489405. DOI: 10.1001/jamaoncol.2020.3370. View

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y . Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016; 34(13):1448-54. DOI: 10.1200/JCO.2015.63.5995. View

Fuchs C, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran S, Van Cutsem E . Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(3):420-435. DOI: 10.1016/S1470-2045(18)30791-5. View

Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martinez E . Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol. 2019; 83(6):1175-1181. PMC: 6779679. DOI: 10.1007/s00280-019-03820-7. View

Janjigian Y, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O . The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021; 600(7890):727-730. PMC: 8959470. DOI: 10.1038/s41586-021-04161-3. View

Klempner S, Maron S, Chase L, Lomnicki S, Wainberg Z, Catenacci D . Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. Oncologist. 2018; 24(4):475-482. PMC: 6459251. DOI: 10.1634/theoncologist.2018-0602. View

Shitara K, Ajani J, Moehler M, Garrido M, Gallardo C, Shen L . Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022; 603(7903):942-948. PMC: 8967713. DOI: 10.1038/s41586-022-04508-4. View

Boku N, Ryu M, Kato K, Chung H, Minashi K, Lee K . Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II.... Ann Oncol. 2018; 30(2):250-258. PMC: 6386029. DOI: 10.1093/annonc/mdy540. View

10.

Cocco E, Scaltriti M, Drilon A . NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018; 15(12):731-747. PMC: 6419506. DOI: 10.1038/s41571-018-0113-0. View

11.

Kang Y, Chen L, Ryu M, Oh D, Oh S, Chung H . Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind,.... Lancet Oncol. 2022; 23(2):234-247. DOI: 10.1016/S1470-2045(21)00692-6. View

12.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

13.

Hecht J, Bang Y, Qin S, Chung H, Xu J, Park J . Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2015; 34(5):443-51. DOI: 10.1200/JCO.2015.62.6598. View

14.

Mathiak M, Warneke V, Behrens H, Haag J, Boger C, Kruger S . Clinicopathologic Characteristics of Microsatellite Instable Gastric Carcinomas Revisited: Urgent Need for Standardization. Appl Immunohistochem Mol Morphol. 2015; 25(1):12-24. PMC: 5147042. DOI: 10.1097/PAI.0000000000000264. View

15.

Thuss-Patience P, Shah M, Ohtsu A, Van Cutsem E, Ajani J, Castro H . Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017; 18(5):640-653. DOI: 10.1016/S1470-2045(17)30111-0. View

16.

Maia A, Wiemann S . Cancer-Associated Fibroblasts: Implications for Cancer Therapy. Cancers (Basel). 2021; 13(14). PMC: 8307167. DOI: 10.3390/cancers13143526. View

17.

Yi J, Lee J, Park S, Park J, Yim D, Park Y . Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer. 2012; 106(9):1469-74. PMC: 3341944. DOI: 10.1038/bjc.2012.100. View

18.

Januszewicz W, Turkot M, Malfertheiner P, Regula J . A Global Perspective on Gastric Cancer Screening: Which Concepts Are Feasible, and When?. Cancers (Basel). 2023; 15(3). PMC: 9913879. DOI: 10.3390/cancers15030664. View

19.

Doebele R, Drilon A, Paz-Ares L, Siena S, Shaw A, Farago A . Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2019; 21(2):271-282. PMC: 7461630. DOI: 10.1016/S1470-2045(19)30691-6. View

20.

Fuchs C, Tomasek J, Yong C, Dumitru F, Passalacqua R, Goswami C . Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2013; 383(9911):31-39. DOI: 10.1016/S0140-6736(13)61719-5. View